Risk and Benefit of Antiplatelet Therapy in COVID-19 Patients with Cancer and Thrombocytopenia: Letter to the Editor.

Nourmohammadi, Hassan; Azami, Golnaz; Taghinezhad, Fakhredin; Shafiei, Elham

Nourmohammadi, Hassan; Azami, Golnaz; Taghinezhad, Fakhredin; Shafiei, Elham.

Nourmohammadi H; Department of Internal Medicine, School of Medicine, Shahid Mostafa Khomaeini Hospital, Ilam University of Medical sciences, Ilam, Iran.
Azami G; Clinical Research Development Unit, Shahid Mostafa Khomeini Hospital, Ilam University of Medical Sciences, Ilam, Iran.
Taghinezhad F; Clinical Research Development Unit, Shahid Mostafa Khomeini Hospital, Ilam University of Medical Sciences, Ilam, Iran.
Shafiei E; Clinical Research Development Unit, Shahid Mostafa Khomeini Hospital, Ilam University of Medical Sciences, Ilam, Iran.

Cancer Invest ; 39(3): 217-218, 2021 03.

Article in English | MEDLINE | ID: covidwho-1007469

Subject(s)

COVID-19/prevention & control; Neoplasms/drug therapy; Platelet Aggregation Inhibitors/therapeutic use; SARS-CoV-2/isolation & purification; Thrombocytopenia/drug therapy; COVID-19/complications; COVID-19/virology; Humans; Neoplasms/complications; Risk Factors; SARS-CoV-2/physiology; Thrombocytopenia/complications

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Thrombocytopenia / Platelet Aggregation Inhibitors / SARS-CoV-2 / COVID-19 / Neoplasms Type of study: Prognostic study Topics: Long Covid Limits: Humans Language: English Journal: Cancer Invest Year: 2021 Document Type: Article Affiliation country: 07357907.2020.1871485

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google